Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt...

Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt Technologies (AIRS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Shattuck Labs (STTK) and NewAmsterdam Pharma Company...

Market Cap	$443.98M	P/E Ratio	N/A
52W High	$8.33	52W Low	$0.71
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	33.8%	52W Position	70.6%
Overall Score	60	Value Score	60
Quality Score	57	Technical Score	63

EPS Current Est	$-0.51	EPS Next Est	$-0.55
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STTK	$6.09	-0.16%	271.34K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STTK	$6.09	-0.2%	271.34K
3
4
5
6

STTK

STTK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Shattuck Labs Inc. Data in Excel

Get Shattuck Labs Inc. Data in Excel